Sol_75N98026Q00881.pdf

REQUEST FOR QUOTATION

(THIS IS NOT AN ORDER)

THIS RFQ IS IS NOT A SMALL BUSINESS SET-ASIDE

15. DATE OF QUOTATION

16. SIGNER

a. NAME (Type or print)

c. TITLE (Type or print)

b. TELEPHONE

AREA CODE

NUMBER

STANDARD FORM 18 (REV. 6/1995)

Prescribed by GSA-FAR (48 CFR) 53.215-1(a)

AUTHORIZED FOR LOCAL REPRODUCTION

Previous edition not usable

8. TO:

b. COMPANYa. NAME

c. STREET ADDRESS

d. CITY e. STATE f. ZIP CODE

9. DESTINATION

a. NAME OF CONSIGNEE

b. STREET ADDRESS

d. STATE e. ZIP CODE

7. DELIVERY

FOB DESTINATION

OTHER

(See Schedule)

10. PLEASE FURNISH QUOTATIONS TO THE

ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date)

IMPORTANT: This is a request for information and quotations furnished are not offers. If you are unable to quote, please so indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotation must be completed by the quoter.

11. SCHEDULE (Include applicable Federal, State and local taxes)

ITEM NUMBER

(a)

SUPPLIES/SERVICES

(b)

QUANTITY

(c)

UNIT

(d)

UNIT PRICE

(e)

AMOUNT

(f)

12. DISCOUNT FOR PROMPT PAYMENT

a. 10 CALENDAR DAYS (%) b. 20 CALENDAR DAYS (%) c. 30 CALENDAR DAYS (%) d. CALENDAR DAYS

NUMBER PERCENTAGE

NOTE: Additional provisions and representations are are not attached.

13. NAME AND ADDRESS OF QUOTER

a. NAME OF QUOTER

b. STREET ADDRESS

c. COUNTY

d. CITY e. STATE f. ZIP CODE

14. SIGNATURE OF PERSON AUTHORIZED TO

SIGN QUOTATION

PAGE OF PAGES

1. REQUEST NUMBER 2. DATE ISSUED 3. REQUISITION/PURCHASE REQUEST NUMBER 4. CERT. FOR NAT. DEF.

UNDER BDSA REG. 2

AND/OR DMS REG. 1

RATING

5a. ISSUED BY 6. DELIVER BY (Date)

NAME TELEPHONE NUMBER

AREA CODE NUMBER

c. CITY

5b. FOR INFORMATION CALL (NO COLLECT CALLS)

National Institutes of Health OD - Office of Logistics and Acquisition Operations 6100 Executive Blvd., Room 6B05 Bethesda, MD 20892-7511

75N98026Q00881

CASSIE RUNNER

+13

014-808827

07/27/2026

08/03/2026 1400 ED

Multiple

The purpose of this NON-COMPETITIVE

COMBINED SYNOPSIS / SOLICITATION is to acquire 32-sample 10x Genomics Five

Prime Single Cell Gene Expression and

Immune Receptor Analysis Kit

The following FAR clauses and Provisions are applicable to this award.

FAR 52.204-13 System for Award

Management Maintenance (Oct 2018)

FAR 52.204-18 Commercial and Government

Entity Code Maintenance (Aug 2020)

HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity

Investigations (Dec 2015)

Continued...

1 8

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGES

NAME OF OFFEROR OR CONTRACTOR

SUPPLIES/SERVICES

(B)

UNIT

(D)

UNIT PRICE

(E)

AMOUNT

(F)

OPTIONAL FORM 336 (4-86)

Sponsored by GSA FAR (48 CFR) 53.110

ITEM NO.

(A)

QUANTITY

(C)

NSN 7540-01-152-8067

75N98026Q00881

FAR 52.212-4 Contract Terms and Conditions -In addition to all the applicable commercial

Products and Commercial Services (Nov 2023)

FAR 52.217-8 Option to Extend Services (Nov

1999)

FAR 52.252-2 CLAUSES INCORPORATED BY REFERENCE

NON-COMPETITIVE

COMBINED SYNOPSIS / SOLICITATION

Title: Acquire 32-sample 10x Genomics Five Prime Single Cell Gene Expression and Immune Receptor Analysis Kit

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.

(ii) The solicitation number is 75N98026Q00881. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition.

This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii).

The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a Firm-Fixed Price award on a non-competitive basis to 10x Genomics, Inc.

6230 Stoneridge Mall Road Pleasanton, California 94588 for 10x Genomics necessary to acquire 32-sample 10x Genomics Five Prime Single Cell Gene Expression and Immune Receptor Analysis Kit.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular, FAC 2026-01, March 2026.

(iv) NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing. The small business size standard is 1,250 employees.

Set aside Status: This requirement is NOT set aside for small business.

(v) Description of Requirement: The required kit shall provide the capability to:

• Perform single-cell gene expression profiling of immune cells isolated from patient samples.

• Perform simultaneous immune receptor sequencing analysis to identify unique B-cell receptor (BCR) and T-cell receptor (TCR) patterns.

• Identify immune cell populations that are expanded within diseased tissue.

• Generate consistent, high-quality single-cell datasets across multiple patient and control samples.

• Support comparative analysis between disease and control groups.

The 32-sample format is required to allow multiple patient and control samples to be processed together, minimizing technical variation between experimental runs and maximizing the use of limited patient-derived tissue specimens.

The acquired reagents are essential for achieving the scientific objectives of the project, including identifying disease-driving immune populations and understanding their contribution to Sjögren’s disease pathology.

(vi) Delivery Location:

NIH, NIDCR

Blake M Warner BLDG 10 room 1A01 10 Center Dr.

Bethesda, md 20895

(vii) [Reserved, if needed]

(viii) The provision at FAR 52.212-1, Instructions to Offerors—Commercial Items, applies to this acquisition. Add any additional instructions as required.

(ix) The provision at FAR 52.212-2, Evaluation—Commercial Items, applies to this acquisition.

(a) A written notice of award or acceptance of an offer, issued to the successful offeror within the time specified in the offer, shall result in a binding contract without further action by either party.

The Government reserves the right to accept any offer (or part of an offer) before the expiration date, whether or not discussions are conducted, unless a written notice of withdrawal is received prior to award. Add additional evaluation criteria as required.

(x) Offerors shall include a completed copy of FAR 52.212-3, Offeror Representations and Certifications—Commercial Items, with their offer.

(xi) FAR 52.212-4, Contract Terms and Conditions—Commercial Items, applies to this acquisition.

(xii) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders—Commercial Items, applies to this acquisition.

(xiii) Additional contract requirements or terms and conditions, as determined necessary by the Contracting Officer and consistent with customary commercial practices: None.

(xiv) The Defense Priorities and Allocations System (DPAS) is not applicable to this requirement.

(xv) Submission Requirements:

Responses must include sufficient information to demonstrate the respondent’s capability to provide the required product or service. Price quotations shall include, at a minimum: unit price, list price, shipping and handling costs, delivery timeframe after award, delivery terms, prompt payment discount terms, F.O.B. point (destination or origin), product or catalog numbers, product descriptions, and any other relevant information.

Evaluation factors may include, but are not limited to: past performance, technical capability, special features, trade-in considerations, expected lifecycle, warranty, maintenance availability, and environmental or energy efficiency considerations.

Respondents claiming to be manufacturers or authorized resellers of a specified brand-name product must provide:

(a) Product, catalog, model, and/or part number(s);

(b) Product description;

(c) Documentation demonstrating that the offered item meets all required salient characteristics;

(d) Quantity;

(e) Estimated price or cost;

(f) Shipping, handling, and/or installation charges; and

(g) Delivery timeframe after receipt of order.

Responses must also include the Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification. All offerors must be actively registered in the System for Award Management (SAM) at www.sam.gov.

All responses must be received by August 3, 2026, and 2PM (1400) EST and must reference solicitation number 75N98026Q00881. Responses may be submitted electronically to cassie.runner@nih.gov.

(xvi) Point of Contact:

Cassie Runner, Contract Specialist, cassie.runner@nih.gov, 301-480-8827 mailto:cassie.runner@nih.gov

Statement of Need (SON)

To: Contracting Officer, Branch, Office of Acquisitions (OA), Office of Management, (OM), National Heart, Lung, and Blood Institute (NHLBI)

From: Project Manager (PM) Blake M. Warner, DDS, PhD, MPH; Principal Investigator & Chief, Salivary

Disorders Unit

Organization: Salivary Disorders Unit, National Institute of Dental and Craniofacial Research, National

Institutes of Health

Project Title: Analysis of T cell and B cell clonality in Sjogren’s Disease

1. Type of Statement of Need

Statement of Need - Equipment Statement of Need – License Agreement

Statement of Need – Supply/Product Statement of Need –Subscription Services

Statement of Need – Maintenance Service Statement of Need – Warranty Agreement

Statement of Need – Other

2. Technical Background and Contractual History 7.105 (a) (1)

This is a new requirement

The 32-plex 10x Genomics 5' GEX/TCR/BCR kit is essential for the proposed studies of B- and T-cell clonality in Sjögren’s disease salivary glands. The project requires simultaneous single-cell characterization of transcriptomes and paired antigen receptor repertoires to identify clonally expanded lymphocyte populations and define their functional states.

No alternative method available in the laboratory can provide this integrated analysis with equivalent single-cell resolution, throughput, and sample multiplexing capacity.

The 32-plex configuration is necessary to reduce technical variation across samples, maximize use of limited patient specimens, and enable statistically meaningful comparison of disease and control groups.

These studies will provide critical mechanistic insight into the role of adaptive immune clonality in SjD pathogenesis and are directly aligned with the project’s goals of identifying disease-driving cell populations and informing future biomarker and therapeutic development.

This is a follow-on requirement

Technical Background:

Contractual History

3. Applicable Conditions 7.105 (a) (2)

Not Applicable

Brand Name Requirement (A brand name justification is attached)

Sole Source Requirement (A sole source justification is attached)

4. Compatibility or Performance Characteristics for Supply of Service 7.105 (a) (4)

Required Features & Benefits of the acquisition:

We require these reagents for high-resolution, single-cell analysis of a novel human minor salivary gland epithelial 3D model system. We require the 5’ GEX/TCR/BCR Immune Profiling Kit from 10x Genomics.

This platform provides the essential capability to perform single-cell RNA sequencing (scRNA-seq) cryopreserved samples, while maintaining high transcript fidelity and cell recovery rates. The kit's high-throughput, scalable, and standardized format allows reproducibility and data harmonization across multiple samples and cohorts.

Required capabilities/performance characteristics/standards

The required kit must support high-throughput single-cell 5' gene expression profiling together with paired V(D)J immune repertoire sequencing for both T-cell receptors (TCR) and B-cell receptors (BCR) from the same cells, with sample multiplexing up to 32 samples in a single workflow. It must provide sufficient sensitivity, cell recovery, and library compatibility to identify clonally expanded B- and T-cell populations and directly link clonotype to transcriptional state.

Why these are necessary and how they relate to the need

These capabilities are necessary because the study objective is to define B- and T-cell clonality in Sjögren’s disease while simultaneously determining the functional state of those same lymphocytes. Bulk repertoire methods or standard expression assays cannot connect clonal expansion with single-cell phenotype. The 32-plex multiplexing capacity is directly related to the need to analyze multiple patient and control samples efficiently, reduce batch effects, conserve limited clinical specimens, and enable rigorous cross-sample comparison. Together, these performance characteristics are essential to generate the integrated single-cell immune profiling data required to identify disease-associated clonal populations in SjD.

Compatibility/Performance Requirements (describe compatibility or interfaces with current and/or future systems/programs, describe any compatibility or performance risks/issues related to the requirement, describe any clearances such as IT security affiliated with this requirement, describe any government furnished equipment affiliated with this requirement)

This system is compatible with Chromium X instrument’s proprietary microfluidics, barcoding chemistry, and software that is widely used throughout the NIH and NIDCR.

5. Delivery or Performance-Period Requirements 7.105 (a) (5)

Period of Performance:

Delivery Requirements:

We anticipate prompt delivery of the reagents, per manufacturer’s specifications withing 30 days of the acceptance of the purchase order.

Title